Aileron Therapeutics Inc expected to post a loss of 8cents a share - Earnings Preview

Rein Therapeutics

18/03/2022 20:32

* Aileron Therapeutics Inc  ALRN.OQ   ALRN.O  is expected
to show
no change in quarterly revenue when it reports  results on March
22 (estimated). 
    * ​Refinitiv's mean analyst estimate for Aileron
Therapeutics Inc
is for a loss of 8 cents per share. For the same quarter last
year, the company reported a loss of 12 cents per share.
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 3 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Aileron
Therapeutics Inc is $3.5​, above​ its last closing price
of $0.43. ​​​
    * Previous quarterly performance (using preferred earnings
measure
in US dollars). ​

 QUARTER       STARMINESM  REFINITIV  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  IBES                 MET,    SE %
               E®          ESTIMATE             MISSED  
 Sep. 30 2021  -0.07       -0.07      -0.07     Met     0
 Jun. 30 2021  -0.07       -0.07      -0.06     Beat    18.2
 Mar. 31 2021  -0.05       -0.05      -0.08     Missed  -50​
 Dec. 31 2020  -0.12       -0.13      -0.12     Beat    5.9
 ​​Sep.        -0.13       -0.15      -0.13     Beat    12.2
 30 2020                                                
 Jun. 30 2020  -0.16       -0.19      -0.14     Beat    25.3​
 Mar. 31 2020  -0.20       -0.20      -0.24     Missed  -18.5
 Dec. 31 2019              -0.27      -0.26     Beat    4.6
 This summary was machine generated March 18 at 20:32 GMT.  All
figures in US dollars  unless otherwise stated